Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Meetings, 69280 [2022-25165]

Download as PDF 69280 Federal Register / Vol. 87, No. 222 / Friday, November 18, 2022 / Notices Dated: November 15, 2022. Lauren K. Roth, Associate Commissioner for Policy. for industry for drug products containing the following active ingredients: TABLE 2—REVISED DRAFT PRODUCTSPECIFIC GUIDANCES FOR DRUG PRODUCTS Acyclovir. Baricitinib. Calcium carbonate; Famotidine; Magnesium hydroxide. Daunorubicin citrate. Deferiprone. Ethinyl estradiol; Norethindrone acetate. Ferric oxyhydroxide (multiple reference listed drugs). Goserelin acetate (multiple reference listed drugs). Icosapent ethyl. Lapatinib ditosylate. Lidocaine. Oxycodone. Progesterone. Ranolazine. Rifaximin. Sodium phosphate, dibasic, anhydrous; Sodium phosphate, monobasic, monohydrate. Sumatriptan succinate (multiple product-specific guidances). For a complete history of previously published Federal Register notices related to product-specific guidances, go to https://www.regulations.gov and enter Docket No. FDA–2007–D–0369. These draft guidances are being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). These draft guidances, when finalized, will represent the current thinking of FDA on, among other things, the product-specific design of BE studies to support ANDAs. They do not establish any rights for any person and are not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. IV. Paperwork Reduction Act of 1995 FDA tentatively concludes that these draft guidances contain no collection of information. Therefore, clearance by the Office of Management and Budget under the Paperwork Reduction Act of 1995 is not required. khammond on DSKJM1Z7X2PROD with NOTICES V. Electronic Access Persons with access to the internet may obtain the draft guidance at https:// www.fda.gov/drugs/guidancecompliance-regulatory-information/ guidances-drugs, https://www.fda.gov/ regulatory-information/search-fdaguidance-documents, or https:// www.regulations.gov. 16:46 Nov 17, 2022 BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Active ingredient(s) VerDate Sep<11>2014 [FR Doc. 2022–25210 Filed 11–17–22; 8:45 am] Jkt 259001 National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development; Notice of Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Member Conflict. Date: December 2, 2022. Time: 11:00 a.m. to 1:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, Room 2131B, Bethesda, MD 20892–7510 (Virtual Meeting). Contact Person: Jolanta Maria Topczewska, Ph.D., Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute Health, 6710B Rockledge Drive, Room 2131B, Bethesda, MD 20892, (301) 451–0000, jolanta.topczewska@nih.gov. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Capstone Centers for Multidisciplinary Research in Child Abuse and Neglect. Date: December 8–9, 2022. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, Room 2137C, Bethesda, MD 20892–7510 (Virtual Meeting). Contact Person: Kimberly L. Houston, MD, Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institute Health, 6710B Rockledge Drive, Room 2137C, PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 Bethesda, MD 20892, (301) 827–4902, kimberly.houston@nih.gov. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Program Project Grants for HIV Research. Date: December 13–14, 2022. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, 6710B Rockledge Drive, Room 2121B, Bethesda, MD 20892–7510 (Virtual Meeting). Contact Person: Christiane M. Robbins, Scientific Review Officer, Scientific Review Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute Health, 6710B Rockledge Drive, Room 2121B, Bethesda, MD 20817, (301) 451–4989, crobbins@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. (Catalogue of Federal Domestic Assistance Program Nos. 93.865, Research for Mothers and Children, National Institutes of Health, HHS) Dated: November 14, 2022. David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–25165 Filed 11–17–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cardiovascular Sciences. Date: December 7, 2022. Time: 8:00 a.m. to 12:00 p.m. E:\FR\FM\18NON1.SGM 18NON1

Agencies

[Federal Register Volume 87, Number 222 (Friday, November 18, 2022)]
[Notices]
[Page 69280]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-25165]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Eunice Kennedy Shriver National Institute of Child Health and 
Human Development; Notice of Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel; Member Conflict.
    Date: December 2, 2022.
    Time: 11:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Eunice Kennedy Shriver 
National Institute of Child Health and Human Development, 6710B 
Rockledge Drive, Room 2131B, Bethesda, MD 20892-7510 (Virtual 
Meeting).
    Contact Person: Jolanta Maria Topczewska, Ph.D., Scientific 
Review Branch, Eunice Kennedy Shriver National Institute of Child 
Health and Human Development, National Institute Health, 6710B 
Rockledge Drive, Room 2131B, Bethesda, MD 20892, (301) 451-0000, 
[email protected].

    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel; Capstone Centers for 
Multidisciplinary Research in Child Abuse and Neglect.
    Date: December 8-9, 2022.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Eunice Kennedy Shriver 
National Institute of Child Health and Human Development, 6710B 
Rockledge Drive, Room 2137C, Bethesda, MD 20892-7510 (Virtual 
Meeting).
    Contact Person: Kimberly L. Houston, MD, Scientific Review 
Officer, Scientific Review Branch, Eunice Kennedy Shriver National 
Institute of Child Health & Human Development, National Institute 
Health, 6710B Rockledge Drive, Room 2137C, Bethesda, MD 20892, (301) 
827-4902, [email protected].

    Name of Committee: National Institute of Child Health and Human 
Development Special Emphasis Panel; Program Project Grants for HIV 
Research.
    Date: December 13-14, 2022.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Eunice Kennedy Shriver 
National Institute of Child Health and Human Development, 6710B 
Rockledge Drive, Room 2121B, Bethesda, MD 20892-7510 (Virtual 
Meeting).
    Contact Person: Christiane M. Robbins, Scientific Review 
Officer, Scientific Review Branch, Eunice Kennedy Shriver National 
Institute of Child Health and Human Development, National Institute 
Health, 6710B Rockledge Drive, Room 2121B, Bethesda, MD 20817, (301) 
451-4989, [email protected].

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.865, 
Research for Mothers and Children, National Institutes of Health, 
HHS)

    Dated: November 14, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-25165 Filed 11-17-22; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.